Infectious mononucleosis

EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001

Retrieved on: 
Monday, December 4, 2023
Guillain–Barré syndrome, Infection, Inflammatory bowel disease, CMO, Multiple sclerosis, Vaccine, Disease, Virus-like particle, Mouse, Human, GMP, EBV, Cancer, Epithelium, CSO, Chronic fatigue syndrome, Epstein–Barr virus, Infectious mononucleosis

The presented data demonstrate that even at low concentrations, non-adjuvanted EBV-001 induces a specific and strong B cell response in mice.

Key Points: 
  • The presented data demonstrate that even at low concentrations, non-adjuvanted EBV-001 induces a specific and strong B cell response in mice.
  • EBViously has generated positive preclinical proof-of-concept data on the immunogenicity of the vaccine candidate.
  • “In addition to a strong preclinical data package, we now have everything in place for the start of clinical trials,” said Axel Polack, M.D., designated CEO of EBViously.
  • It is also known that people infected with EBV are 32 times more likely to develop multiple sclerosis.

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Retrieved on: 
Monday, October 30, 2023
Neoplasm, PDUFA, Food, Dysgeusia, Rash, Vitamin, Vonoprazan, Abdomen, Clarithromycin, Liver, Chills, Pain, Hypersensitivity, Infection, Allergy, Azithromycin, Rilpivirine, Diarrhea, Liver disease, Tablet, Medicine, Genetically modified bacteria, Drug, Safety, Patient, Chronic pain, DUAL, Catalent, History, Weight loss, Colchicine, GERD, Helicobacter pylori, Fever, Calcium channel, Common, PAS, Jaundice, CGA, Abdominal pain, FDA, Infectious mononucleosis, Headache, Aes, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Candidiasis, Erythromycin, Urine, Hypertension, Breast milk, Blood, AE, Pharmaceutical industry, Vaccine, Soft drink, Teahouse, Antibiotics, Medicinal plants, Dietary supplement, Birth control, Amoxicillin, Emtricitabine/rilpivirine/tenofovir

The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.

Key Points: 
  • The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.
  • VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) are co-packaged prescription medicines for the treatment of a Helicobacter pylori (H. pylori) bacterial infection in adults.
  • It is not known if VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are safe and effective in children.
  • Stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK if you are diagnosed with mononucleosis and call your doctor right away.

QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus

Retrieved on: 
Wednesday, October 4, 2023
Vaccine, IGRA, DNA, QIAGEN, QGEN, Central nervous system, Senior, EBV, SARS-CoV-2, COVID-19, Nonpathogenic organisms, Cytomegalovirus, Research, Post-transplant lymphoproliferative disorder, Multiple sclerosis, Antibody, Lyme, MS, DiaSorin, Infectious mononucleosis, QuantiFERON, RUO, HIV disease progression rates, Patient, Risk, Blood, PTLD, Immune system, Gamma ray, Lymphocyte, Health, Virus, NYSE, Epstein–Barr virus infection, Autoimmunity, Conditional sentence, Dentistry

Venlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay.

Key Points: 
  • Venlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay.
  • In organ transplant recipients, EBV is associated with post-transplant lymphoproliferative disorder (PTLD), a potentially fatal complication after solid organ transplantation.
  • Measuring the T-cell response to EBV can help researchers better understand immune responses to the virus.
  • This approach is different from but complementary to traditional tests, which focus on detecting viral DNA or antibodies produced in response to the virus.

Long COVID could be caused by the virus lingering in the body. Here's what the science says

Retrieved on: 
Saturday, June 10, 2023
Inflammation, Infection, Tissue, Heart, Epstein–Barr virus, DNA, Autoantibody, HIV, Vaccination, SARS-CoV-2, Eye, Herve Bostan Amani, Viral, Brain, COVID, Cell, RNA, Antibody, Autoimmunity, HERV, Psoriasis, Thought, Measles, Inflammatory bowel disease, Nose, Viral disease, Herpes virus, Dementia, Protein, Patient, Risk, Infectious mononucleosis, Blood, Immune system, Conditional sentence, Colonoscopy, DSM-IV codes, Autoimmune disease, Area studies, Research, Virus, Autopsy, Fatigue, Pharmaceutical industry, Vaccine, Copper

When symptoms last longer than 12 weeks, the condition is known as long COVID.

Key Points: 
  • When symptoms last longer than 12 weeks, the condition is known as long COVID.
  • Long COVID encompasses up to 200 different symptoms.
  • One factor that may be associated with long COVID is that the virus hasn’t fully cleared from the body after the initial infection.

Other viruses lurk in the body

    • This means the virus conceals itself within cells and remains dormant.
    • HIV, in particular, can remain dormant in infected cells throughout the body.
    • Several studies have shown COVID can also reactivate the Epstein-Barr virus, which has remained in the body in a latent state.

How do we know COVID stays in the body?

    • SARS-CoV-2 RNA was detected in at least half the samples of heart, lymph glands, eye, nerve, brain and lung tissue tested.
    • These patients had asymptomatic COVID and were PCR-negative from swabs of the nose and throat at four months.
    • Initial studies did not always suggest a strong relationship between the long-term detection of SARS-CoV-2 and long COVID symptoms.

How might the delay in clearing the virus impact people with long COVID?

    • We have previously shown immune dysfunction and inflammation persist up to eight months in people with long COVID that initially had mild to moderate disease.
    • Read more:
      When does COVID become long COVID?
    • Antibodies reactive to Epstein-Barr virus are elevated in people with long COVID suggesting Epstein-Barr virus reactivation, likely through activating the immune system.
    • This should include examination of viral RNA and protein in both blood and tissues in people with long COVID independent of disease severity.

EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases

Retrieved on: 
Monday, April 3, 2023
Vaccine, GMP, Human, Epstein–Barr virus, Genetics, Lymphoproliferative disorders, EBV, CSO, ME/CFS, Immunity, EST, CMO, Multiple sclerosis, Incidence, Infectious mononucleosis, Chronic fatigue syndrome, DSM-IV codes, PTLD, Immune system, Cancer, Walter, Washington Convention Center, Virus-like particle, Convention center, Disease

The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the

Key Points: 
  • The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the
    Walter E. Washington Convention Center in Washington, DC.
  • The first candidate, named EBV-001, is based on non-infectious EBV-derived virus-like particles (VLPs).
  • EBViously has generated positive preclinical proof-of-concept data on the immunogenicity of the vaccine candidate.
  • As infectious mononucleosis is a known risk factor for multiple sclerosis, there is great hope that our vaccine may also reduce the incidence of this chronic neurodegenerative autoimmune disease.”

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

Retrieved on: 
Wednesday, November 30, 2022
Infection, COVID-19, Patient, SAN, Communication, PEM, SD, Congress, Lung, RECIST, Nausea, Malignant transformation, Cell, Risk, Epstein–Barr virus, Poster, Safety, Infectious mononucleosis, Therapy, Fatigue, Government, NPC, Oncology, HDAC, Creatinine, EBV, Neoplasm, Immunodeficiency, Nasopharyngeal carcinoma, Stomach, Plasma, Research, Webcast, Infrared spectroscopy correlation table, Lymphoma, European Society for Medical Oncology, Valganciclovir, Liver, Pharmaceutical industry, Vaccine

Key data reported in the abstract include:

Key Points: 
  • Key data reported in the abstract include:
    Nana-val was well tolerated with no dose limiting toxicities (DLTs) reported.
  • Plasma EBV DNA titers decreased or remained stable in both patients achieving SD, while rising in patients with progressive disease.
  • The company anticipates initiating the Phase 2 randomized expansion portion of the Phase 1b/2 trial in the second half of 2023.
  • This Phase 1b/2 trial ( NCT05166577 ) is an open-label, multinational trial evaluating Nana-val alone and in combination with pembrolizumab.

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

Retrieved on: 
Monday, September 19, 2022
Adult, Risk, Time, Infectious mononucleosis, Shire, COVID-19, European Institute, Stomach, Business administration, Cell, PTC Therapeutics, Company, Population, Degenerative disease, Hematology, Private Securities Litigation Reform Act, HDAC, Industry, Therapy, Epstein–Barr virus, Patient, Infection, Government, Cancer, Nasopharyngeal carcinoma, CEO, University of Cambridge, Immunodeficiency, Goal, Nasdaq, Board of directors, Valganciclovir, Malignant transformation, General manager, Board, RNA, Silence Therapeutics, Biotechnology, Research, EBV, SEC, Marketing, Multimedia, Lymphoma, Communication, Mark's, INSEAD, Management, Pharmaceutical industry, Vaccine, Director

SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession of its President and Chief Executive Officer, Ivor Royston, M.D. to Mark Rothera, who was appointed as President and CEO and member of the Board of Directors, effective today. Dr. Royston will support the leadership transition and continue to serve as a member of the Board of Directors.

Key Points: 
  • to Mark Rothera, who was appointed as President and CEO and member of the Board of Directors, effective today.
  • Dr. Royston will support the leadership transition and continue to serve as a member of the Board of Directors.
  • Prior to joining Viracta, Mr. Rothera served as President and CEO of Silence Therapeutics, a clinical-stage organization focused on developing RNA therapies for hematology, cardiovascular and rare diseases.
  • Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

Grid Biosciences Announces License Agreement with NIH for Epstein-Barr Virus Vaccine

Retrieved on: 
Monday, August 29, 2022
National, Human, CEO, National Institute, National Institute of Allergy and Infectious Diseases, Degenerative disease, Stomach, Hodgkin lymphoma, Laboratory, Infection, Vaccine, EBV, Burkitt lymphoma, Multiple sclerosis, Mouse, Nasopharyngeal carcinoma, NIH, Vaccine Research Center, Patent, NEW, Epstein–Barr virus, Infectious mononucleosis, NIAID, Lymphoma, List of life sciences, Cancer, Grid

NEW YORK, Aug. 29, 2022 /PRNewswire-PRWeb/ -- Grid Biosciences ("Grid"), a biotechnology company, today announced the signing of a license agreement for the development of a vaccine against Epstein-Barr virus ("EBV") with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the National Institutes of Health ("NIH"). The agreement includes access to NIH's patent rights in EBV envelope proteins that the virus uses to gain entry into human cells.

Key Points: 
  • Grid Biosciences signs license agreement for the development of a vaccine against Epstein-Barr virus with the National Institute of Allergy and Infectious Diseases.
  • NEW YORK, Aug. 29, 2022 /PRNewswire-PRWeb/ -- Grid Biosciences ("Grid"), a biotechnology company, today announced the signing of a license agreement for the development of a vaccine against Epstein-Barr virus ("EBV") with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the National Institutes of Health ("NIH").
  • The agreement includes access to NIH's patent rights in EBV envelope proteins that the virus uses to gain entry into human cells.
  • The forward-looking statements in this press release are based on information available to Grid as of the date hereof.

Worldwide Mononucleosis Diagnostic Industry to 2027 - Rising Health Awareness and Knowledge Among Patients is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, April 25, 2022
Infectious Diseases, Science, Health, Other Science, Infectious mononucleosis, Population, Epstein–Barr virus, Adolescence, Growth, Central, United Nations, EBV, First Nations in Ontario, Antibody, Disease, Risk, UN, Vaccine

A monospot test, also known as a heterophile antibody test, is a rapid test for the detection of infectious mononucleosis caused by the Epstein-Barr virus (EBV).

Key Points: 
  • A monospot test, also known as a heterophile antibody test, is a rapid test for the detection of infectious mononucleosis caused by the Epstein-Barr virus (EBV).
  • Such studies greatly increase the acceptance of monospot test type among the patient population, thereby, contributing to the segment's growth.
  • For instance, Launch Diagnostics offers a rapid latex test for the detection of heterophile antibodies specific to Infectious Mononucleosis (IM).
  • The high youth population indicates the significant demand for mononucleosis diagnostic tests.

Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors

Retrieved on: 
Wednesday, April 20, 2022
Patient, Head, HDAC, Immunodeficiency, Infectious mononucleosis, Moores Cancer Center, Population, Adult, Hannah, Stomach, Research, Immunotherapy, MD, NPC, Infection, Markey Cancer Center, Associate, PRMC, Department, Executive Committee, Valganciclovir, Cell, Malignant transformation, Standard of care, KOL, University of California, Nasdaq, Neoplasm, EBV, Nasopharyngeal carcinoma, Webcast, Division, Multimedia, University, Epstein–Barr virus, Risk, Therapy, Pharmacotherapy, Vaccine, Pharmaceutical industry

SAN DIEGO, April 20, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on Nana-val (nanatinostat and valganciclovir) for the treatment of advanced Epstein-Barr virus-positive (EBV+) solid tumors on Wednesday, April 27, 2022, at 11:00 AM EDT.

Key Points: 
  • Additionally, members of Viracta's management team will provide an overview of the ongoing Phase 1b/2 clinical trial evaluating Nana-val in patients with recurrent or metastatic NPC and other advanced EBV+ solid tumors.
  • Preclinical data supporting the use of Nana-val in solid tumors and the program's future outlook will also be discussed.
  • Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patient's life.
  • Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.